STONEBRANCH
9.4.2024 15:01:34 CEST | Business Wire | Press release
Stonebranch, a leading provider of service orchestration and automation solutions, today published the 2024 Global State of IT Automation Report: IT Automation and Orchestration Benchmarks for IT Ops, DevOps, CloudOps, and DataOps Teams, its third-annual benchmark study on the automation priorities, expectations, and challenges of IT professionals worldwide.
“We're pleased to release our Global State of IT Automation Report, now in its third year,” said Giuseppe Damiani, Stonebranch CEO. “This research offers a detailed analysis of current trends, challenges, and opportunities in IT automation and orchestration, providing valuable benchmarks for IT professionals worldwide. We're passionate about contributing to the IT industry's evolution and innovation, and we're dedicated to helping our customers realize their automation potential.”
Key Insights from the 2024 Global State of IT Automation Report
The 2024 Global State of IT Automation Report is based on a survey of IT automation professionals and executives, conducted by Censuswide between January 24 – February 5, 2024.
This year's report unveils critical insights into the evolving landscape of IT automation, offering a unique lens through which IT Ops, DevOps, CloudOps, and DataOps professionals can view the future of automation and orchestration technologies. Three notable emerging trends include:
- Automation is Evolving into Orchestration: Driven by a desire to orchestrate across complex hybrid IT environments, 82% of respondents plan to replace legacy IT automation tools or add new automation tools to the mix.
- Democratization of Automation Continues to Grow: 88% of respondents enable end-users across the business with self-service access to IT automation. Those who plan to add or replace IT automation tools with a more modern solution cited a desire to add self-service as the leading reason for change.
- Companies Prefer a Mix of On-Prem and Cloud Environments: In only one year, hybrid IT usage has doubled from 34% to 68%. Organizations are deciding where to store data — either on-prem or cloud — on a case-by-case basis. This approach is efficient and flexible but poses a challenge when it comes to automating and orchestrating these environments.
- Machine Learning Pipelines are Evolving and Growing in Importance: A significant 74% of respondents have already incorporated data and ML pipelines to operationalize their AI-driven initiatives. This is an indicator of many companies’ strong commitment to the pivotal role of AI in shaping their future success.
Peter Baljet, Stonebranch CTO, notes, “Our findings show that companies are adapting their IT automation and orchestration strategies to meet the specific challenges that come with cloud technologies. In the complex world of today’s hybrid IT environments, automation is crucial to enhance performance, secure systems, and control costs.”
To fully explore the research results:
- Download the full report — Stonebranch 2024 Global State of IT Automation: IT Automation and Orchestration Benchmarks for IT Ops, DevOps, CloudOps, and DataOps Teams.
- Watch the research results webinar, which highlights key trends and insights from the report, as well as Stonebranch’s recommendations for success.
About Stonebranch
Stonebranch builds IT orchestration and automation solutions that transform business IT environments from simple IT task automation into sophisticated, real-time business service automation. No matter the degree of automation, the Stonebranch platform is simple, modern, and secure. Using the Stonebranch Universal Automation Center platform, enterprises can seamlessly orchestrate workloads and data across technology ecosystems and silos. Headquartered in Atlanta, Georgia, with points of contact and support throughout the Americas, Europe, and Asia, Stonebranch serves some of the world’s largest financial, manufacturing, healthcare, travel, transportation, energy, and technology institutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409835235/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom